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The tumor suppressor promyelocytic leukemia (PML) protein is fused to the retinoic acid
receptor alpha in patients suffering from acute promyelocytic leukemia (APL).Treatment of
APL patients with arsenic trioxide (As2O3) reverses the disease phenotype by a process
involving the degradation of the fusion protein via its PML moiety. Several PML isoforms are
generated from a single PML gene by alternative splicing.They share the same N-terminal
region containing the RBCC/tripartite motif but differ in their C-terminal sequences. Recent
studies of all the PML isoforms reveal the specific functions of each. Here, we review the
nomenclature and structural organization of the PML isoforms in order to clarify the vari-
ous designations and classifications found in different databases.The functions of the PML
isoforms and their differential roles in antiviral defense also are reviewed. Finally, the key
players involved in the degradation of the PML isoforms in response to As2O3 or other
inducers are discussed.
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INTRODUCTION
The promyelocytic leukemia (PML) gene was originally identified
in acute promyelocytic leukemia (APL) where it is fused to the
retinoic acid receptor alpha (RARA) gene as a result of a t(15; 17)
chromosomal translocation (de The et al., 1991; Kakizuka et al.,
1991; Pandolfi et al., 1991). This translocation leads to the syn-
thesis of a chimeric protein, named PML-RARα, which blocks the
differentiation of hematopoietic progenitor cells. In normal cells,
PML forms nuclear speckles, known as PML nuclear bodies (NBs).
In APL cells, due to the expression of PML-RARα (Dyck et al.,
1994; Weis et al., 1994), NBs are dispersed as microspeckles. Thus,
alteration of PML NB functions by PML-RARα expression may
contribute to leukemogenesis. The treatment of APL patients with
arsenic trioxide (As2O3) reverses the disease phenotype and cures
up to 70% of APL patients (Mathews et al., 2010). Remarkably,
by targeting the PML moiety, As2O3 promotes PML-RARα degra-
dation which leads to PML NB reformation (Zhu et al., 1997).
Also, As2O3 increases PML SUMOylation and promotes its inter-
action with the poly-SUMO-dependent ubiquitin E3 ligase that is
responsible for proteasome-mediated PML degradation, namely
RNF4 for Really interesting New gene (RING) Finger protein 4
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008).
Both the covalent conjugation of SUMO to PML and the
non-covalent interaction of SUMO with the SUMO Interact-
ing Motif (SIM) of PML are required for the integrity and
normal function of PML NBs (Ishov et al., 1999; Shen et al.,
2006). PML NBs are dynamic structures, which harbor a few
permanently (PML, Sp100, and SUMO) and numerous tran-
siently residing proteins depending on different conditions (i.e.,
transformation, stress, interferon (IFN) treatment, and viral infec-
tions). The list of cellular and viral proteins recruited on PML
NBs, based on co-localization studies, is growing. Interestingly,
based on database analyses, 166 proteins were found to be asso-
ciated with PML (Van Damme et al., 2010). Since the discovery
of PML in APL, numerous studies have been conducted to link
PML and PML NBs with various cellular functions including
senescence, apoptosis, protein degradation, and antiviral defense
(Everett and Chelbi-Alix, 2007; Bernardi et al., 2008; Krieghoff-
Henning and Hofmann, 2008; Geoffroy and Chelbi-Alix, 2011;
Rabellino and Scaglioni, 2013). In fact, the interaction of PML
with certain viral proteins or with the PML-RARα chimeric pro-
tein causes PML NB disruption and abolishes normal PML NB
functions.
Promyelocytic leukemia is the organizer of the NBs. Several
PML isoforms, designated PMLI to PMLVIIb, which differ within
their C-terminal end, are expressed by alternative splicing of a
single PML gene. The variations in the COOH-terminal regions
lead to the specific functions of each PML isoform. For exam-
ple, in the context of antiviral defense, during varicella-zoster
virus (VZV) (Reichelt et al., 2011) or encephalomyocarditis virus
(EMCV) (Maroui et al., 2011) infection, only PMLIV sequesters
viral proteins in PML NBs and inhibits viral production. In recent
years, although few comparative studies have been performed with
all the PML isoforms, increasing evidence suggests that each PML
isoform exhibits specific functions.
In this review, we will discuss first the nomenclature and struc-
tural organization of the PML isoforms in order to clarify the
classifications that are found in different databases. Then, we will
review the role of key players in the As2O3-induced degradation of
PML isoforms as compared to other inducers. Also, we will analyze
how a particular PML isoform confers viral resistance by seques-
tering viral proteins in PML NBs and the strategies developed by
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these viruses to disrupt these structures. Finally, we will summarize
the functions attributed to each isoform.
NOMENCLATURE AND STRUCTURE OF THE PML ISOFORMS
NOMENCLATURE FOR THE PML ISOFORMS
Promyelocytic leukemia isoforms are generated by alternative
splicing from a single PML gene, which includes nine exons
according to the original nomenclature defined by Jensen et al.
(2001) (Figure 1A). Exons 7 and 8 can be divided into exons
7a, 7b, 8a, and 8b. Some isoforms also contain the 7ab intronic
sequence in whole (7ab) or in part (7ab∗) (Figure 1B). There
are six nuclear PML isoforms designated PMLI to PMLVI and
one cytoplasmic isoform, PMLVIIb (called PMLVII in some pub-
lications) (Figure 1B) (Jensen et al., 2001). The isoforms are
numbered in the inverse order of their size, PMLI being the longest
and PMLVIIb the shortest. They share the same N-terminal region
but have different C-termini due to alternative splicing of exons
4–9 (Figure 1). In addition to the seven main isoforms (PMLI to
PMLVIIb), other potential PML isoforms might be expressed as
a result of putative alternative splicing of exons 4, 5, and 6. Let-
ters are added to the names of the isoforms to indicate the lack of
particular exons; “a” is for isoforms without exon 5 (amino acids
419–466),“b”for isoforms without exon 5 and 6 (amino acids 419–
552) and “c” for isoforms without exon 4, 5, and 6 (amino acids
395–552). For example, PMLIVa corresponds to PMLIV isoform
without exon 5 and PMLVIb corresponds to PMLVI without exon
5 and exon 6. Since the “b” and “c” variants do not have the nuclear
localization signal (NLS) encoded by exon 6 (Figure 2A), they are
likely to be cytoplasmic as is the case for PMLVIIb. Note that in
addition to the loss of exons 5 and 6, exon 7a, which is found in
PMLI to PMLVI, is also missing in PMLVIIb.
Interestingly, the splicing of exons 5 and 6 in the mRNA vari-
ants PMLI to PMLVI (which retain exon 7a) results in a frameshift
which places a STOP codon at the beginning of exon 7a and,
thus, leads to transcripts coding for a single cytoplasmic protein
cPML∆5-6 (corresponding to PMLIb to PMLVIb). Note that the
eight nucleotide intronic sequence within PMLVI is located at
the end of exon 6. This short sequence is not present after the
splicing of exons 5–6. Therefore, the PMLVIb protein will be iden-
tical to the other “b” variants. cPML∆5-6 (423 amino acids) and
PMLVIIb (435 amino acids) differ from each other by only 12
amino acids at their C-terminal end. The C-terminus of cPML∆5-
6 (RNALW) is encoded by the very beginning of exon 7a (identical
to the C-terminus of PMLVI), whereas the C-terminus of PMLVIIb
(VPPPAHALTGPAQSSTH) is encoded, out of frame, by a part of
exon 7b. In contrast, the splicing of exons 4, 5, and 6 results in
transcripts which code for cytoplasmic proteins which contain the
specific C-terminal region of each isoform (PMLIc to PMLVIc).
In the case of exon 5 splicing, the transcripts encode nuclear PML
isoforms, which contain the corresponding C-terminal region of
each (PMLIa to PMLVIa). Further studies are needed to confirm
the suggestion of Fagioli et al. (1992) that all isoforms can be
expressed endogenously from a, b, or c mRNA variants.
This nomenclature (Jensen et al., 2001) differs from other clas-
sifications provided by NCBI, GenBank, and UniProt (Table 1).
The Jensen nomenclature is usually used by researchers in the
PML field for its convenience and its coherence relative to the
organization of the PML gene, the mRNA spliced variants, and the
resulting protein isoforms. For further clarification, we provide a
compilation of the various names given to PML isoforms in these
classification systems as well as their accession numbers and length
(Table 1). Since the names given to PML isoforms within differ-
ent databases conflict, the systematic inclusion in publications of
the accession number would permit the proper identification of
the PML isoforms used. Of note, the name of some exons dif-
fers between the classification originally used (Jensen et al., 2001)
and the NCBI database (see Figure 1A legend). For example, the
exons 8a–8b in PMLIV correspond to NCBI exon 8b (Figure 1A).
Finally, a few of the listed isoforms correspond to polymorphic
sequences with different numbers of tandem repeats (e.g., PMLII
isoforms with two or three repeats of the pentapeptide SSPAH
leading to proteins with 824 or 829 amino acids, respectively)
(Table 1).
DOMAIN STRUCTURE OF PML ISOFORMS
Promyelocytic leukemia is a member of the tripartite motif
(TRIM) family (Reymond et al., 2001; Nisole et al., 2005). The
RBCC/TRIM motif (at amino acids 57–253 in exons 1–3) har-
bors a C3HC4 RING-finger, two B-boxes (B1 and B2), and an
α-helical coiled-coil domain (Figure 2A) (Kastner et al., 1992).
As a member of the TRIM family, PML corresponds to TRIM19.
Specific names have been given to the PML isoforms according to
the TRIM classification (Table 1).
All the PML isoforms share exons 1–3, which encode the
RBCC/TRIM motif at their N-terminal end (Figure 2A). This
motif is essential for PML NB formation and PML homodimer-
ization via the coiled–coiled domain. The differences in the C-
terminal parts of the PML isoforms (Figure 1B) determine the
different partners and, thus, the specific functions of each iso-
form. Several motifs have been identified in the C-termini of PML
isoforms (Figure 2A). The nuclear export signal (NES) (amino
acids 704–713/exon 9) is found only in PMLI, consistent with the
nuclear and cytoplasmic distribution of this isoform. The SIM is
present only in PMLI to PMLV. The SIM hydrophobic core (VVVI
encoded by exon 7a, amino acids 556–559) is adjacent to specific
serines (S560, S561, S562, and S565) which are substrates for the
Casein Kinase-2 (CK2) (Scaglioni et al., 2006; Shen et al., 2006).
Note that these two studies used the PML isoform PMLIVa, which
lacks exon 5, where the SIM hydrophobic core is located at amino
acids 508–511 and the CK2 phosphorylated sites at positions S512,
S513, S514, and S517. Both the SIM hydrophobic core and the
CK2-phosphorylation sites are missing in the nuclear PMLVI (due
to a short retained intron at the end of exon 6 which introduces a
frameshift in exon 7a) and in the cytoplasmic PMLVIIb (absence
of exon 7a) (Figure 1).
DOMAIN STRUCTURE OF PML-RARα
In the t(15; 17) translocations of APL, two major breakpoints
have been identified in the PML gene that is fused to RARA (de
The et al., 1991; Pandolfi et al., 1991; Kastner et al., 1992). The
RARA breakpoint invariably occurs within the second intron of
this gene. The breakpoints in PML are located between exons
3 and 4 (at amino acid 394) and between exons 6 and 7 (at
amino acid 552) and lead to two PML-RARα fusion proteins, S
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FIGURE 1 | Structure of the PML gene and the PML isoforms generated
by alternative splicing. (A) PML gene (NCBI accession no. NG_029036.1)
includes nine exons (1–9) according to the nomenclature described by Jensen
et al. (2001). Exons 7 and 8 can be subdivided into exons 7a, 7b, 8a, and 8b.
Note that the 7ab sequence corresponds to the retained intronic region
between exon 7a and 7b found in PMLIII and PMLV. There are some
differences for exons 6, 7, and 8 between the nomenclature of Jensen and
that of the NCBI (see accession numbers inTable 1). Exon 6 in Jensen’s
nomenclature corresponds to exon 6a in NCBI, exon 7b of PMLIII to exon 7c,
exons 7a-7ab-7b to exon 7b, exon 7b of PMLVIIb to exon 7d, exons 8a-8b to
exon 8b. Alternative splicing of the PML gene leads to seven main mRNA
variants. The start and stop codons are symbolized for each variant. The
retained intronic sequences in PMLIII and PMLV (between exons 7a and 7b),
as well as in PMLVI (between exons 6 and 7a) are indicated. Retained introns
introduce a frameshift in exon 7b of PMLIII and in exon 7a of PMLVI. Only
exons are represented at the same scale. Intron length: 1–2: 3,062 bp/2–3:
24,351 bp/3–4: 1,448 bp/4–5: 7,644 bp/5–6: 440 bp/6–7: 1,063 bp/7ab:
640 bp/7–8: 6,594 bp/8–9: 844 bp. (B) The length of the main PML isoforms
(PMLI to PMLVIIb) encoded by the different mRNA variants and their exon
composition, from the initiating methionine to the end of the protein, are
shown. The asterisks indicate that only part of the sequence (either exon or
intron) is retained (due to the presence of an in frame STOP codon).
for Short fusion and L for Long fusion (Figure 2B). The PML-
RARα L isoform is expressed in approximately 55% of adult
patients with APL, whereas the S isoform is expressed in approx-
imately 35% of the patients (Zelent et al., 2001). In addition,
another chimeric protein in APL can be generated by the alter-
native splicing of exon 5 in PML-RARα transcripts (de The et al.,
1991; Kastner et al., 1992). All the PML-RARα fusion proteins
possess the RBCC motif but lack the various C-terminal regions,
which are characteristic of each PML isoform including the SIM
and CK2 phosphorylating sites (in exon 7a). Although the short
PML-RARα isoform differs from the long one since it lacks the
PML NLS (in exon 6) and some of the SUMOylation sites in
exons 4 and 6, it maintains a nuclear localization due to its RARα
moiety.
The t(15; 17) translocation disrupts one allele of the PML gene
and,consequently, reduces PML mRNA expression. The formation
of heterodimers between PML and PML/RARα via the coiled-coil
domain facilitates the sequestration of PML out of the NBs. In
APL, the chimeric PML-RARα protein alters the normal local-
ization of PML NBs from the speckled pattern to a pattern of
micro-dispersed tiny dots. All the PML NB-associated partners are
delocalized in APL cells. The disruption of PML and RARα func-
tions are implicated in APL pathogenicity because PML-RARα
impairs both nuclear receptor-induced differentiation and PML-
triggered apoptosis (Nason-Burchenal et al., 1998; Mistry et al.,
2003). Thus, inactivation of the PML growth suppressor activity
may result in uncontrolled growth of APL cells.
KEY STEPS IN As2O3-INDUCED DEGRADATION OF PML
ISOFORMS
Since the discovery that As2O3 reverses the disease phenotype of
APL patients, numerous studies have been conducted to elucidate
the mechanisms of action of this therapeutic agent in normal and
cancer cells. As2O3 was shown to promote PML and PML-RARα
degradation. Briefly, before As2O3 induces degradation, PML is
phosphorylated, is transferred from the nucleoplasm to the nuclear
www.frontiersin.org May 2013 | Volume 3 | Article 125 | 3
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FIGURE 2 | Domain organization of the PML and the PML-RARα
proteins. (A) The domains, the motifs, and their amino acid (aa) positions
relative to the PMLI isoform are presented. These include the RBCC/TRIM,
the NLS, the NES, and the SIM hydrophobic core (VVVI) motifs as well as
the adjacent sequences containing the CK2-phosphorylation sites. The three
major (K65, K160, and K490) and five minor (K226, 380, 400, 497, 616)
SUMOylation sites are shown. A bracket indicates the common region
shared by PMLI to PMLV and encoded by exons 1 to 7a. The SIM encoded
by exon 7a is missing in PMLVI and PMLVIIb. The K616 encoded by exon 8a
is found only in PMLI and PMLIV. The NES is present only in PMLI. (B) The
short and the long PML-RARα fusion proteins and their translocation
breakpoints are shown.
matrix, is SUMOylated and it interacts, via the SUMO moiety,
with RNF4. These steps are followed by PML ubiquitination and
the recruitment of proteasome components to PML NBs, which
results in proteasome-dependent degradation of PML (Figure 3).
These findings, together with others, establish that PML NBs are
sites of protein modification and degradation (Fogal et al., 2000;
Lallemand-Breitenbach et al., 2001, 2008; Pampin et al., 2006;
Tatham et al., 2008; Malloy et al., 2013).
As2O3 INDUCES THE TRANSFER OF PML TO THE NUCLEAR
MATRIX-ASSOCIATED NBs
In the nucleus, PML is expressed mostly in the diffuse nuclear
fraction of the nucleoplasm (RIPA soluble fraction) while a small
fraction is found in the matrix-associated NBs (RIPA resistant
fraction) (Zhu et al., 1997; Muller et al., 1998; Porta et al., 2005;
Pampin et al., 2006; El Mchichi et al., 2010). PML is detected
mainly as the bright immunofluorescent speckles, which form the
NBs even though PML is more abundant in the nucleoplasm.
In response to As2O3, PML is phosphorylated rapidly (within
10 min) in its N-terminus (T28, S36, S38, and S40) by ERK1/2
mitogen-activated protein kinase (Hayakawa and Privalsky, 2004)
and, then, transferred from the nucleoplasm to the nuclear matrix
(Lallemand-Breitenbach et al., 2001). Interestingly, this transfer
occurs independently of PML SUMOylation as a SUMOylation-
deficient mutant (PMLIII-3KR) still is transferred to the nuclear
matrix in cells treated with As2O3 (Lallemand-Breitenbach et al.,
2001). Note that poliovirus infection also very rapidly induces
PML phosphorylation by the ERK1/2 pathway, followed by the
transfer of PML from the nucleoplasm to the nuclear matrix
(Pampin et al., 2006). However, further experiments using PML
Frontiers in Oncology | Molecular and Cellular Oncology May 2013 | Volume 3 | Article 125 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nisole et al. Differential roles of PML isoforms
Table 1 | Nomenclature of the PML isoforms.
Jensen et al.
name
Isoform
length
TRIM name GenBank
name
GenBank
accession
number
NCBI name NCBI
accession
number
UniProt
name
UniProt
accession
number
PMLI 882 aa TRIM19 alpha TRIM19 alpha AF230401 Isoform 1 NP_150241.2 PML-11 P29590-1
860 aa2 PML-11 M79462
PMLIa5 834 aa PML-11 P29590-11
PMLII 854 aa3,4 TRIM19 delta TRIM19 delta AF230404
829 aa TRIM19 kappa TRIM19 kappa AF230410 Isoform 9 NP_150242.1 PML-21 P29590-8
824 aa4 TRIM19 gamma TRIM19 gamma AF230403 PML-8 P29590-3
802 aa2,4 PML-31 M79464
PMLIIa5 781 aa Isoform 11 NP_150253.2 PML-13 P29590-13
PMLIII 641 aa PML S50913 PML-31 P29590-9
PMLIV 633 aa TRIM19 zeta TRIM19 zeta AF230406 Isoform 6 NP_002666.1 PML-4 P29590-5
633 aa Myl (PML) X63131
PMLIVa5 585 aa TRIM19 lambda TRIM19 lambda AF230411 Isoform 10 NP_150252.1 PML-12 P29590-12
PMLV 611 aa TRIM19 beta TRIM19 beta AF230402 Isoform 2 NP_150243.2 PML-5 P29590-2
589 aa2 PML-21 M79463
PMLVI 560 aa TRIM19 epsilon TRIM19 epsilon AF230405 Isoform 5 NP_150247.2 PML-6 P29590-4
560 aa PML-11 M73778
538 aa2 PML-3B M80185
PMLVIb6 423 aa TRIM19 iota TRIM19 iota AF230409 Isoform 7 NP_150249.1 PML-14 P29590-14
423 aa TRIM19 eta TRIM19 eta AF230407
PMLVIIb7 435 aa TRIM19 theta TRIM19 theta AF230408 Isoform 8 NP_150250.2 PML-7 P29590-10
1Conflicting name given for different isoforms in GenBank and UniProt.
2Protein product reported to start at Met23 in GenBank even if the mRNA sequence contains the sequence coding for the first 22 amino acids (aa) including the Met1.
3Same sequence as for AF230403 (824 aa) but which contains an extra 30 aa repeat in exon 7b (repeated sequence: QRGISPPHRIRGAVRSRSRSLRGSSHLSQW).
4Two repeats of the pentapeptide SSPAH instead of three in exon 7b in PMLII.
5Isoform missing exon 5 (aa 416–466).
6Isoform missing exons 5 and 6 (aa 416–552) that is identical to cPML∆5-6 (seeTable 5). Note that, as described in Jensen et al. (2001) and reported by the NCBI
and UniProt databases, this isoform is missing the intron sequence 5′-GTAGGGAG-3′ (shown in Figure 1A) present in PMLVI at the end of exon 6.
7Due to the absence of exons 5 and 6, this isoform is referred as PMLVIIb instead of PMLVII.
FIGURE 3 | Key steps in As2O3-induced PML degradation. Steps 1 and 2 are SIM-independent whereas steps 3 and 4 require the PML SIM.
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phosphorylation-deficient mutants are needed to demonstrate
that PML phosphorylation by ERK1/2 is sufficient to induce the
transfer of PML toward the nuclear matrix.
As2O3 ENHANCES PML SUMOylation
PML SUMOylation and PML NB formation
Promyelocytic leukemia NBs provide a nuclear platform for post-
translational modifications such as phosphorylation, acetylation,
and SUMOylation (Cheng and Kao, 2012; Schmitz and Grishina,
2012). SUMOylation is the most studied post-translational modi-
fication of PML. SUMOylation is believed to occur in the nuclear
matrix and it has important consequences for PML functions
because it can affect the localization, stability, and ability of PML
to interact with other partners. SUMOylation of PML is critical
for NB formation since PML SUMO-deficient mutants are unable
to form these structures (Ishov et al., 1999). The requirement for
a functional SUMO machinery for PML NB formation also was
demonstrated in cells derived from knockout mice for SUMO1
or the E2 SUMO-conjugating enzyme, UBC9 (Nacerddine et al.,
2005; Evdokimov et al., 2008). Recently, it has been reported that
the SUMO E3 ligase PIAS1, for Protein Inhibitor of Activated
STAT, interacts with the PML RBCC motif and enhances PML
SUMOylation (Rabellino et al., 2012).
Modification by SUMO is a common property of PML NB-
associated proteins. According to the current literature, almost
40% of PML partners have been confirmed to be SUMOylated.
This suggests that PML NBs are enriched sites for SUMOylated
proteins and may function as nuclear SUMOylation hotspots (Van
Damme et al., 2010).
SUMOylation sites in PML
Initial studies identified three lysine residues (K65, K160, K490
located, respectively, in the RING-finger, B1 box, and NLS) in PML
as major SUMOylation sites. These lysine residues are all part
of the canonical SUMOylation consensus motif ψKxE/D or its
inverted version E/DKxψ (Kamitani et al., 1998; Da Silva-Ferrada
et al., 2012) (Table 2). PML is modified by covalent coupling of
SUMO1, SUMO2, and SUMO3 to these three lysine residues (K65,
K160, K490) (Kamitani et al., 1998). However, residual SUMOy-
lation of PMLIII-3KR (mutated in K65, K160, and K490) still is
detected in the presence of overexpressed SUMO and is enhanced
upon overexpression of PIAS1 or As2O3 treatment (Galisson et al.,
2011; Rabellino et al., 2012). This indicates that PML still can be
SUMOylated even in the absence of the three major SUMOylation
sites, although the extent of this modification is significantly lower
than that observed with PMLIII wild-type. These observations are
consistent with the identification of five additional SUMOylation
sites (K226, K380, K497, K400, K616) which correspond to poten-
tial minor SUMOylation sites, three of which are compliant with
the canonical consensus or its inverted version (K226, K380, and
K616) (Vertegaal et al., 2006; Galisson et al., 2011) (Table 2). These
SUMOylation sites are present in the nuclear PMLI to PMLVI,
except K616 encoded by exon 8a that is only found in PMLI and
PMLIV. Note that residues K380 and K400 were identified previ-
ously as sites of polyubiquitination in response to As2O3 (Tatham
et al., 2008). Futures studies will reveal the potential role of these
new SUMOylation sites in PML functions.
As2O3 enhances poly-SUMOylation of nuclear PML isoforms
Except for the cytoplasmic PMLVIIb, all the PML isoforms (PMLI
to PMLVI) are SUMOylation substrates (Maroui et al., 2012). PML
SUMOylation is enhanced by various stimuli including As2O3
treatment and viral infections (Muller et al., 1998; Lallemand-
Breitenbach et al., 2001; Pampin et al., 2006; El Mchichi et al.,
2010). This post-translational modification is associated with
the recruitment of PML NB partners and an increase in PML
NB size. Interestingly, the inhibition of ERK1/2 with the MEK1
inhibitor U0126 abrogates both As2O3- and poliovirus-induced
PML SUMOylation (Hayakawa and Privalsky, 2004; Pampin et al.,
2006).
It has been suggested that As2O3 binds directly to cysteine
residues in the zinc finger motifs located within the RBCC domain
of PML leading to PML oligomerization and increased interaction
of PML with the SUMO-conjugating enzyme UBC9 (Zhang et al.,
Table 2 | Major and minor PML SUMOylation sites.
Consensus PML SUMOylation sites Exon Motif Reference
CM ΨKxE/D K226: LKCD Minor 3 B2 Vertegaal et al. (2006)
K616: LKID Minor 8a –
ICM E/DxKΨ K65: EAKC Major 2 RING Kamitani et al. (1998)
K380: EFKV Minor 3 – Galisson et al. (2011)
HCSM ΨΨΨKxE K160: WLFKHE Major 2 B1 Kamitani et al. (1998)
NDSM ΨKxExxEEE K490: IKMESEE Major 6 NLS
Other K400: VSKKASP Minor 4 – Galisson et al. (2011)
K497: EEGKEAR Minor 6 –
The longest PML isoform, PMLI, contains 30 lysines and those targeted by SUMO are numbered in reference to this isoform. Most identified PML SUMOylation
sites identified correspond to known SUMO Consensus Motif (CM) and its variants (Da Silva-Ferrada et al., 2012).These include the inverted version of the CM (ICM:
Inverted Consensus Motif) and variants of the CM with extensions that favor SUMOylation such as an amino-terminal hydrophobic extension (HCSM: Hydrophobic
Cluster SUMO Motif) or a carboxy-terminal acidic extension (NDSM: Negatively charged amino-acid-Dependent SUMO Motif). Hydrophobic residue (Ψ), any amino
acid (x), SUMOylation target lysine (in red).
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2010). Furthermore, due to its oxidative properties, As2O3 also
stimulates the oligomerization of PML by enhancing PML inter-
molecular disulfide bond formation, a process, which favors PML
NB formation (Jeanne et al., 2010). Subsequently, As2O3 stimu-
lates the formation of higher molecular weight poly-SUMO chains
on all nuclear PML isoforms (Maroui et al., 2012).
As2O3 PROMOTES THE INTERACTION OF ALL SUMOylated PML
ISOFORMSWITH RNF4
RNF4 is a SUMO targeted ubiquitin ligase (STUbL),which harbors
a RING domain that strongly interacts with poly-SUMOylated
PML owing to its multiple SIMs (Lallemand-Breitenbach et al.,
2008; Tatham et al.,2008). These interactions occur with all nuclear
SUMOylated PML isoforms (PMLI to PMLVI) and are increased
in response to As2O3 (Maroui et al., 2012). These observations are
consistent with the higher affinity of RNF4 for polySUMO chains
and the strong induction of PML poly-SUMOylation elicited by
As2O3 (Lallemand-Breitenbach et al., 2008; Tatham et al., 2008).
The interaction of RNF4 with PML involves indirect binding via
the SUMO moiety of PML-SUMO conjugates since no interac-
tion was detected with a SUMOylation-deficient PML mutant
(PMLIII-3KR) (Percherancier et al., 2009).
As2O3 is known to induce proteasomal degradation of PML
(Zhu et al., 1997). RNF4 is a key player in PML proteasomal
degradation since it acts as a poly-SUMO-specific E3 ubiquitin
ligase that triggers the ubiquitination of poly-SUMOylated PML
(Lallemand-Breitenbach et al., 2008; Tatham et al., 2008). As sug-
gested in these studies, the ubiquitination can occur on either
moiety of the PML-SUMO conjugates. Very recently, while this
review was under revision, it was reported that Arkadia also acts
as a poly-SUMO-targeted ubiquitin ligase implicated in As2O3-
induced PML degradation (Erker et al., 2013) (see below). This
finding sheds a new light on the complexity of the mechanisms of
PML degradation in response to As2O3.
PML SIM IS REQUIRED FOR As2O3-INDUCED PML UBIQUITINATION
AND DEGRADATION
SUMO proteins, as other ubiquitin-like proteins, not only can be
conjugated covalently to proteins but also can form non-covalent
interactions with various proteins containing a SIM (Song et al.,
2004). The SIM (also named SBD for SUMO Binding Domain)
identified in PML (Shen et al., 2006) is encoded by exon 7a, which is
only translated in PMLI to PMLV. The hydrophobic core (VVVI)
of the PML SIM is the minimal requirement for an interaction
with SUMO and adjacent acidic and serine residues (SSSEDS-
DAE) follow this core (Figure 2). The serine residues are targets
for CK2-phosphorylation (Scaglioni et al., 2006). The negative
charges intrinsic to acidic residues or introduced by phosphory-
lation favor the interaction between SIMs and SUMO (Stehmeier
and Muller, 2009).
The SIM of PML is not essential for NB formation as
PMLVI, which lacks the SIM, still is able to form NBs when
expressed in PML−/− cells (Brand et al., 2010). However, the
PML SIM hydrophobic core (VVVI) mediates non-covalent
interactions with SUMOylated proteins and promotes their
recruitment into PML NBs (Shen et al., 2006). In addition,
the CK2-phosphorylation sites (SSSEDSDAE) are required for
the positive regulation of this process, suggesting the phospho-
dependent recruitment of some SUMOylated proteins (Percher-
ancier et al., 2009). Therefore, both the SIM hydrophobic core
and the adjacent CK2-phosphorylation sites are involved in the
integrity and the normal function of PML NBs. Furthermore, the
SIM is not required for PML SUMOylation and interaction with
RNF4 as shown by results obtained with PMLVI which lacks the
SIM or with a PMLIII-SIMVVVI mutant (VVVI mutated to AAAS)
(Percherancier et al., 2009; Maroui et al., 2012). In contrast, the
SIM hydrophobic core is implicated in PML degradation since
PMLVI or a PMLIII-SIMVVVI mutant are not degraded efficiently
upon As2O3 treatment of cells (Percherancier et al., 2009; Maroui
et al., 2012) (Figure 3). The resistance of PMLVI or a PMLIII-
SIMVVVI mutant to the degradation process is due to their inability
to be polyubiquitinated and to efficiently recruit the proteasome
components to PML NBs (Maroui et al., 2012). Thus, not all PML
nuclear isoforms are efficiently degraded in response to As2O3.
Remarkably, PMLVI resistance to As2O3-induced degradation is
bypassed by overexpression of RNF4 (Maroui et al., 2012).
Taken together, these results demonstrate that the SIM
hydrophobic core is required for efficient As2O3-induced PML
degradation, an event that occurs after the recruitment of RNF4
by poly-SUMOylated PML.
As2O3 IS A THERAPEUTIC AGENT OF APL PATIENTS
Treatment of APL patients with all-trans retinoic acid (ATRA)
or As2O3, reverses the disease phenotype and promotes PML-
RARα degradation, which leads to PML NB reformation (Zhu
et al., 1997, 1999). ATRA and As2O3 degrade the fusion protein
by targeting RARα and PML, respectively, by two different mech-
anisms. APL was first shown to be sensitive to the differentiation
therapy with ATRA (Huang et al., 1988). However some patients
became resistant to treatment with ATRA. Interestingly, As2O3
is beneficial even in APL patients who have relapsed. The action
of As2O3 in APL occurs through the induction of apoptosis and
partial differentiation (Chen et al., 1997).
Promyelocytic leukemia-RARα is, like PML, phosphorylated by
ERK1/2 in response to As2O3 (Hayakawa and Privalsky, 2004) and,
then, highly conjugated to SUMO2/3 (Lallemand-Breitenbach
et al., 2008), since it retains two of the three major PML SUMOy-
lation sites at K65 and K160. As2O3 causes the poly-SUMOylation
of PML-RARα and thus promotes its interaction with RNF4
leading to its proteasome-dependent degradation (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008; Weisshaar et al., 2008).
Thus, RNF4-mediated PML-RARα ubiquitination and degrada-
tion plays an important role in the APL therapeutic response to
As2O3.
Surprisingly, the SIM hydrophobic core that is required for
As2O3-induced RNF4-dependent degradation and the adjacent
CK2-phosphorylation sites are missing in the chimeric PML-
RARα. However, in APL cells, the SIM-containing PML from
the normal allele may oligomerize with PML-RARα and facilitate
RNF4-dependent degradation of the fusion protein. Furthermore,
PML-RARα degradation could occur through other pathways that
promote PML degradation in response to As2O3 independently of
RNF4 (e.g., USP7-dependent PML degradation, see below). This
may account for the delayed As2O3-induced degradation of the
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expressed PML-RARα in PML−/− cells compared to wild-type
cells (Jeanne et al., 2010; Lallemand-Breitenbach et al., 2012).
OTHERS PATHWAYS OF PML DEGRADATION
In addition to the PML NB disruption that occurs upon viral
infection or in APL cells, expression of the PML protein is fre-
quently lost in human cancers from multiple origins (Gurrieri
et al., 2004). Emerging studies reveal that proteasome-dependent
degradation is a mechanism by which tumor cells restrict PML
expression (reviewed in Chen et al., 2012). The best character-
ized PML degradation pathway implicates RNF4 as detailed above.
Below, we will review other pathways controlling PML stability.
CASEIN KINASE-2
Casein Kinase-2 (CK2) is a ubiquitously expressed and highly
conserved serine/threonine kinase that targets PML. After CK2-
mediated phosphorylation, PML undergoes ubiquitin-mediated
degradation (Scaglioni et al., 2006). Cell treatments with osmotic
shock, anisomycin, or UV radiation, which result in PML phos-
phorylation, polyubiquitination, and degradation, may exert their
effects, in part, via CK2. Indeed, two specific CK2 inhibitors
(TBB and TBCA) abrogate osmotic shock-induced PML degra-
dation. Scaglioni and colleagues showed that CK2 phosphorylates
PMLIVa at multiple sites (S512–514 and S517) and that CK2 trig-
gers PML degradation through the phosphorylation of PMLIVa
S517 (corresponding to S565 in PMLI to PMLV) (Figures 1 and 2).
These CK2-phosphorylation sites are found in the nuclear PMLI
to PMLV and are missing in PMLVI as well as in PML-RARα. CK2-
phosphorylation depends upon PIAS1-induced PML SUMOyla-
tion. SUMOylation enhances the interaction of PML with CK2,
which leads to PML phosphorylation and degradation (Rabellino
et al., 2012). Interestingly, the CK2-phosphorylation sites are not
required for As2O3-induced PML degradation, since, a polyserine
mutant deficient for CK2-phosphorylation (PMLIII-S560-565A)
is still sensitive to As2O3-induced degradation (Percherancier
et al., 2009).
Therefore, as illustrated in Figure 4, different inducers use at
least two independent pathways for PML degradation. As2O3-
induced degradation depends upon the recruitment of RNF4
and requires the hydrophobic core of the SIM but not the CK2-
phosphorylation sites. CK2-dependent PML degradation relies on
CK2 sites adjacent to the hydrophobic core of the PML SIM. At
present, the ubiquitin E3 ligase responsible for CK2-dependent
PML degradation remains to be identified. Furthermore, it would
be interesting to determine if the CK2-mediated degradation of
PML triggered by various inducers such as osmotic shock, ani-
somycin, and UV radiation also requires the hydrophobic core of
the SIM in addition to its adjacent CK2-phosphorylation sites.
Noticeably, CK2-phosphorylation sites favor the interaction of
the hydrophobic core of PML SIM with SUMO-modified partners
and, thus, contribute to normal PML NB function (Shen et al.,
2006; Percherancier et al., 2009).
Taken together these findings suggest that CK2 and RNF4 may
negatively regulate the level of PML by two independent path-
ways under oncogenic or physiological conditions. Interestingly
PML mutants resistant to CK2-phosphorylation increase tumor
suppressive functions. Also, an inverse correlation between PML
protein levels and CK2 kinase activity was observed in human lung
cancer-derived cell lines and primary cell cultures (Scaglioni et al.,
2006, 2008).
ARKADIA
Arkadia/RNF111 is a member of the RING-finger ubiquitin ligase
superfamily that promotes activation of the TGF-signaling path-
way and acts as a signal-dependent E3 ubiquitin ligase for SnoN
and Ski (Levy et al., 2007). Very recently, it has been reported that
Arkadia is a novel poly-SUMO-targeted ubiquitin ligase which is
involved in As2O3-induced PML degradation (Erker et al., 2013).
Arkadia contains in its N-terminus three successive SIMs that
mediate non-covalent interactions with poly-SUMO2. The third
SIM, VVDL, of Arkadia is the most relevant for this interaction
(Erker et al., 2013). Arkadia binds to As2O3-induced SUMO-
modified PML or PML-RARα only when the SIMs of Arkadia are
intact, thus indicating that Arkadia interacts with these SUMOy-
lated substrates via its SIMs. Specific binding of Arkadia to poly-
SUMOylated PML leads to the accumulation of Arkadia in PML
NBs shortly after As2O3 cell treatment. In addition, knockdown
of Arkadia (Erker et al., 2013) results, as observed for RNF4
(Tatham et al., 2008), in the accumulation of SUMOylated PML
in response to As2O3. Arkadia and RNF4 do not act synergisti-
cally but most probably, act independently during this degradation
process. In addition to RNF4, these new findings clearly iden-
tify Arkadia, as a second SUMO-dependent E3 ubiquitin ligase
implicated in As2O3-induced degradation of poly-SUMOylated
PML.
UBIQUITIN-SPECIFIC PROTEASE 7
USP7/HAUSP (Herpes virus-Associated Ubiquitin-Specific Pro-
tease) was identified as an interacting partner of HSV-1 ICP0 E3
ubiquitin ligase and was found to be associated with PML NBs
(Everett et al., 1997). USP7 interacts with and controls PML sta-
bility, independently of its deubiquitinase activity (Sarkari et al.,
2011). CK2 and RNF4 regulators of PML catabolism are dispens-
able for USP7-mediated PML NB disruption and PML degrada-
tion (Sarkari et al., 2011). Thus, USP7 induces PML degradation
by another pathway that does not implicate phosphorylation
of PML by CK2 or polyubiquitination by RNF4. Interestingly,
USP7 depletion indicates that USP7 participates in As2O3-induced
degradation of PML (Sarkari et al., 2011). Since USP7 promotes
PML ubiquitination, it may recruit an E3 ubiquitin ligase or
an inducer of PML degradation. This represents an additional
PML degradation pathway the mechanism of which remains to be
determined.
HMGA2
The High-Mobility Group A protein 2 (HMGA2) is an architec-
tural transcription factor implicated in cell growth, regulation of
transcription, and transformation. It has been reported to medi-
ate a proteasome-dependent PML degradation. SUMOylation of
HMGA2 is required to destabilize PML. In addition, As2O3 was
shown to increase both HMGA2 SUMOylation and its recruit-
ment in nuclear foci around PML NBs (Cao et al., 2008). However,
the implication of HMGA2 in As2O3-induced PML degradation
remains to be determined.
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FIGURE 4 | Role of CK2 phosphorylated serines and the VVVI
hydrophobic core in PML degradation. In response to osmotic shock,
anisomycin, or UV radiation, PML is phosphorylated at the CK2 serine sites
(red) adjacent to the SIM hydrophobic core (VVVI) (blue) leading to PML
degradation. In contrast, As2O3-induced PML degradation requires the SIM
VVVI.
PEPTIDYL-PROLYL CIS-TRANS ISOMERASE
The peptidyl-prolyl cis-trans isomerase (Pin1) has been shown to
bind phosphorylated PML, promoting a conformational change
that results in PML degradation (Reineke et al., 2008). The inter-
action of Pin1 with PML is enhanced by various stimuli such as
EGF or hypoxia, which induce the phosphorylation of various ser-
ine residues within exon 6 of all nuclear PML isoforms (Lim et al.,
2011; Yuan et al., 2011). ERK2 and CDK1/2 are kinases involved
in the phosphorylation-dependent mechanism that leads to Pin1-
mediated PML degradation (Lim et al., 2011; Yuan et al., 2011).
Remarkably in this case, SUMOylation of PML blocks its interac-
tion with Pin1 and prevents its degradation (Reineke et al., 2008).
This degradation process is independent of RNF4 activity and
CK2-phosphorylation (Yuan et al., 2011). Interestingly, the role
of the Cullin3-KLHL20 ubiquitin ligase in PML polyubiquitina-
tion and in Pin1-dependent proteasomal degradation was recently
demonstrated (Yuan et al., 2011). This process requires CDK1/2
phosphorylation of PML on S518 (found in all nuclear PML and
in the long PML-RARα isoform) and prolyl cis/trans isomeriza-
tion of P519 by Pin1, two events which promote the interaction of
KLHL20 with PML. In contrast to RNF4, KLHL20-based E3 ligase
polyubiquitinates unSUMOylated PML (Yuan et al., 2011). Inter-
estingly, higher levels of Pin1 and KLHL20 in human prostate
cancer correlate with a decrease of PML expression and disease
progression (Yuan et al., 2011).
E6-ASSOCIATED PROTEIN
E6-Associated Protein (E6AP) was initially identified as the E3
ligase that acts with the human papillomavirus E6 protein to
promote p53 degradation (Scheffner et al., 1993). E6AP is the
founding member of the HECT (homologous to the E6AP C-
terminus) family of ubiquitin ligases. E6AP and PML interact
and colocalize in PML NBs. Also, E6AP promotes the ubiq-
uitination and proteasomal degradation of all nuclear PML
isoforms (Louria-Hayon et al., 2009; Wolyniec et al., 2012).
A SUMOylation mutant, PMLIV-K160R, is still ubiquitinated
and degraded by E6AP (Louria-Hayon et al., 2009). The high
PML levels in multiple tissues and primary cells derived from
E6AP deficient mice further demonstrate the regulation of PML
by E6AP. In addition, an increase in E6AP expression is cor-
related with PML down-regulation in human Burkitt’s lym-
phoma specimens and a number of B cell lymphoma cell lines
(Wolyniec et al., 2012). Inversely, down-regulation of E6AP in
B cell lymphoma cells restores PML expression with a con-
current induction of cellular senescence in these cells. Taken
together, these results suggest that E6AP expression contributes,
in part, to PML degradation and to the loss of PML in B
cell lymphoma. Also, E6AP may contribute to As2O3-induced
PML degradation since exogenous E6AP, together with As2O3,
markedly reduces the half-life of PML (Louria-Hayon et al.,
2009).
www.frontiersin.org May 2013 | Volume 3 | Article 125 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nisole et al. Differential roles of PML isoforms
HERPES SIMPLEX VIRUS 1 AND EPSTEIN–BARR VIRUS
Studies with DNA and RNA viruses provide another example
of alteration of PML NBs and regulation of PML stability. Such
alterations could be a viral strategy to evade a cellular resistance
mechanism. This field has been covered in numerous reviews
(Everett and Chelbi-Alix, 2007; Tavalai and Stamminger, 2008;
Geoffroy and Chelbi-Alix, 2011).
The best-studied virus involved in PML degradation is Her-
pes simplex virus 1 (HSV-1) (Everett et al., 1998; Chelbi-Alix
and de The, 1999; Boutell and Everett, 2013). The immediate
early protein, ICP0 protein, mediates HSV-1-induced proteasome-
dependent PML degradation. This process correlates with the
ability of ICP0 to interact with USP7 (Everett et al., 1997). ICP0,
as a viral RING-finger ubiquitin ligase of the STUbL family, is one
of the first proteins expressed during HSV-1 infection and it local-
izes in and disrupts PML NBs. ICP0 binds to SUMOylated PML
through its own viral multiple SIM-like sequences (Boutell et al.,
2011) and it induces PML degradation by two distinct mecha-
nisms. Like RNF4, ICP0 preferentially induces the degradation
of all SUMO-modified PML isoforms but, unlike RNF4, ICP0
also targets PMLI in a SUMO-independent manner (Boutell et al.,
2011; Cuchet-Lourenco et al., 2012). In addition, the CK2 pathway
is not implicated since CK2 inhibitors do not compromise HSV-1-
or ICP0-induced PML degradation (Smith et al., 2011).
Epstein–Barr virus (EBV), another herpes virus, induces PML
degradation and PML NB disruption via the expression of
Epstein–Barr nuclear antigen 1 (EBNA1) protein. EBNA1 dis-
rupts PML NBs by inducing the degradation of all PML isoforms
(Sivachandran et al., 2008). PML degradation by EBNA1 requires
two EBNA1 domains. One domain binds CK2 and the other binds
USP7. These interactions result in the formation of a ternary
complex between EBNA1, CK2, and USP7 (Sivachandran et al.,
2008, 2010). The implication of USP7 is demonstrated by the fact
that PML degradation is not observed with EBNA1 mutant defec-
tive in USP7-binding or with wild-type EBNA1 when USP7 is
depleted (Sivachandran et al., 2008). Also, by using an antibody
specific for PML phospho-S517, EBNA1 was shown to enhance
PML phosphorylation (Sivachandran et al., 2010). Interestingly,
EBV-positive gastric carcinoma tumors have reduced PML stain-
ing as compared to EBV negative samples (Sivachandran et al.,
2012). Therefore, the loss of PML and PML NB disruption by
EBNA1 is one mechanism by which EBV may contribute to the
development of gastric cancer.
Thus, elucidating the mechanisms implicated in virus-
dependent PML degradation could help to provide strategies for
developing antiviral therapies that prevent viral infections.
INTRINSIC ANTIVIRAL DEFENSE MEDIATED BY A SPECIFIC
PML ISOFORM
One key function of the PML NBs is to protect cells from viral
infection. This antiviral defense is counteracted by viruses, which
have developed various strategies using the SUMO pathway to alter
the localization and/or expression of PML. A role of PML in viral
resistance in vivo is indicated by the increased sensitivity of PML
knockout mice (as compared to the wild-type mice) to lympho-
cytic choriomeningitis virus (LCMV) and to vesicular stomatitis
virus (VSV) infections (Bonilla et al., 2002). These observations
corroborate with in cellulo data which demonstrate that fibrob-
lasts derived from these mice (PML−/− MEFs) exhibit enhanced
replication for RNA viruses such as LCMV (Djavani et al., 2001),
rabies virus (Blondel et al., 2002), and EMCV (El Mchichi et al.,
2010) (Table 3). Also, PML depletion in human cells results in
enhanced replication of DNA viruses from the herpes family such
asCytomegalovirus (HCMV) (Tavalai et al., 2006) andVZV (Kyrat-
sous and Silverstein, 2009) (Table 3). The implication of PML
in antiviral defense against RNA and DNA viruses from differ-
ent families has been demonstrated in cells depleted for PML or
in cells stably expressing individual PML isoforms (reviewed in
Everett and Chelbi-Alix, 2007; Geoffroy and Chelbi-Alix, 2011).
Further on, we will discuss the role of PML in antiviral defense
by taking examples from the picornavirus family (EMCV) (Maroui
et al., 2011) and the herpes virus family (VZV) (Reichelt et al.,
2011) because these studies were performed with all the PML iso-
forms and they demonstrate how a single PML isoform, PMLIV,
confers viral resistance. Also, only PMLIV confers resistance to
rabies virus by an unknown mechanism (Blondel et al., 2010)
(Table 4).
PML AND EMCV
Encephalomyocarditis virus belongs to the Picornaviridae family
(Cardiovirus genus). The virion is composed of a single-stranded
RNA molecule of positive polarity. Although EMCV replication
occurs in the cytoplasm, it has been reported that, during the
early steps of infection or in transfected cells, the viral protease
3C (3Cpro) and the 3D polymerase (3Dpol) colocalize with PML
in NBs (El Mchichi et al., 2010; Maroui et al., 2011). The 3Dpol
Table 3 | Only PMLIV confers resistance to EMCV, rabies virus, and VZV.
Virus Higher viral production Inhibition of viral
production
Mechanism Reference
RNA viruses
EMCV
Absence of PML (MEFs PML−/−)
PMLIV Sequestration of
3D pol in PML NBs
El Mchichi et al. (2010); Maroui et al. (2011)
Rabies virus PMLIV ND Blondel et al. (2002, 2010)
DNA virus
VZV Depletion of PML (Human cells) PMLIV Sequestration of
ORF23 in PML NBs
Kyratsous and Silverstein (2009); Reichelt et al.
(2011)
ND, not determined.
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is a central element of viral RNA replication complexes and the
protease 3Cpro is the central enzyme in the viral cleavage cascade.
Promyelocytic leukemia has been implicated in resistance to
EMCV since PML−/− MEFs are more sensitive to EMCV than
wild-type cells (El Mchichi et al., 2010) and because specific PML
isoforms, PMLIV, and its variant PMLIVa (missing exon 5), pro-
tect cells from EMCV infection (Table 3). PMLIV inhibits viral
RNA replication by interacting with the viral polymerase, 3Dpol,
and by sequestering it within PML NBs (Maroui et al., 2011). No
other PML isoform is able to recruit the 3Dpol into PML NBs
and to impair EMCV multiplication (Maroui et al., 2011). The
SUMOylation of PML is required for its anti-EMCV activity and,
accordingly, a SUMOylation-deficient mutant (PMLIV-3KR) is
neither able to recruit the 3Dpol within PML NBs nor to impair
viral production (Maroui et al., 2011). PMLIV and PMLIVa dif-
fer from the other PML isoforms by the presence of exons 8a
and 8b in their common C-terminal region. Exon 8b of PMLIV
is required for the sequestration of 3Dpol within PML NBs that
leads to viral resistance. PMLIV has an intrinsic antiviral property
against EMCV that occurs independently of IFN synthesis. Impor-
tantly, specific depletion of PMLIV reduces the capacity of IFN to
protect cells from EMCV infection (Maroui et al., 2011). These
findings reveal the mechanism by which PML confers resistance
to EMCV and a new pathway for the mediation of the antiviral
activity of IFN against EMCV.
Encephalomyocarditis virus has developed various strategies to
counteract cellular antiviral defenses that include blocking IFN-
α/β gene transcription (Hato et al., 2007) and degrading PML
in a SUMO- and proteasome-dependent manner (El Mchichi
et al., 2010) (Table 4). Remarkably, as observed with As2O3,
infection with EMCV results in recruitment of PML toward the
nuclear matrix followed by its degradation (Zhu et al., 1997;
Porta et al., 2005; El Mchichi et al., 2010). Soon after infec-
tion, EMCV induces the transfer of PML from the nucleo-
plasm to the nuclear matrix, both in IFN-treated and PMLIII-
expressing cells. EMCV also enhances PML conjugation to SUMO
(SUMO-1, -2, and -3) which leads to an increase in PML NB
size. The viral 3Cpro and the proteasome component colocalize
with PML within the NBs. This process leads to PML degrada-
tion in a SUMO- and proteasome-dependent manner and to a
decrease of PML NBs (Table 4). Indeed, EMCV-induced degra-
dation requires that PMLIII bind covalently to SUMO and this
Table 4 | EMCV and VZV alter PML localization and/or expression.
Virus PML NB alteration PML degradation Reference
EMCV Loss of PML NBs SUMO- and
proteasome-dependent
PML degradation*
El Mchichi et al.
(2010)
VZV ORF61 SIM-mediated
PML NB disruption
No PML degradation in
ORF61-expressing cells
or in VZV-infected cells
Wang et al.
(2011)
*There is no degradation of PML in infected cells stably expressing PMLIV
because PMLIV inhibits EMCV production.
degradation process is reduced in cells depleted of SUMO1 or
SUMO2/3. As observed with As2O3, the SIM of PML is not
required for EMCV-enhanced PML SUMOylation, but unlike
As2O3 (Maroui et al., 2012), the hydrophobic core of the SIM
is dispensable for EMCV-mediated PML degradation (El Mchichi
et al., 2010).
As PMLIV protects cells from EMCV infection, its protein level
remained constant (Maroui et al., 2011) whereas the expression
level of the other nuclear PML isoforms is decreased upon EMCV
infection (El Mchichi et al., 2010 and unpublished data). These
results reveal a strategy used by EMCV to destabilize PML through
mechanisms implicating SUMO and the proteasome. However,
the SUMO-dependent pathways contributing to EMCV-induced
PML degradation remain to be elucidated.
PML AND VZV
Varicella-zoster virus belongs to the Herpesviridae family and is
classified as an alpha herpes virus. Two VZV proteins have impor-
tant roles in viral replication. The first protein derives from an
open reading frame (ORF23) that encodes a conserved capsid pro-
tein, which is specifically sequestered by PMLIV within PML NBs
thus leading to VZV restriction. The second protein is ORF61 that
counteracts this antiviral defense by disrupting the PML NBs.
Depletion of PML protein enhances VZV replication in cell cul-
ture, indicating a role for PML in the host cell defense (Kyratsous
and Silverstein,2009). Among the six nuclear PML isoforms (PMLI
to PMLVI), only PMLIV sequesters the ORF23 capsid protein in
PML NBs in infected cells and significantly inhibits viral infection
(Reichelt et al., 2011) (Table 3). This antiviral property requires
the unique C-terminal region of PMLIV, which contains exons 8a
and 8b as the PMLIV-∆8ab mutant is unable to interact with the
ORF23 protein. Thus, the specific interaction of the C-terminal
part of PMLIV with the ORF23 capsid leads to sequestration of
the capsid in PML NBs and to VZV restriction. Interestingly, PML
was recently shown to restrict VZV pathogenesis in human skin
xenografts in mice (Wang et al., 2011).
Like other herpes viruses, VZV disrupts PML NBs for effi-
cient replication. VZV encodes an ICP0 ortholog, open reading
frame 61 (ORF61) that, similarly to ICP0, transcriptionally acti-
vates viral promoters and enhances the infectivity of viral DNA
(Moriuchi et al., 1993; Mossman et al., 2000). VZV-mediated PML
NB disruption is achieved by ORF61 protein via its SIMs. ORF61
is a viral RING-finger protein with three functional SIMs, like
those present in cellular proteins such as RNF4. In the absence
of functional ORF61 SIMs, PML NBs are not affected and VZV
infection is impaired (Wang et al., 2011). The finding that ORF61
requires its SIMs to alter PML NBs provides new evidence that
non-covalent SIM-SUMO interactions between PML and a viral
protein can counteract the intrinsic anti-VZV activity mediated by
PML NBs. PML protein expression is persistent in VZV-infected
cells and ORF61 protein alone can cause PML NB disruption with-
out degrading PML proteins (Table 4). Unlike RNF4, ORF61 does
not promote PML degradation.
Promyelocytic leukemia NBs provide an intrinsic host defense
against VZV infection and the ORF61 SIM-dependent PML NB
disruption is used by VZV to counteract the antiviral activity of
these nuclear structures.
www.frontiersin.org May 2013 | Volume 3 | Article 125 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nisole et al. Differential roles of PML isoforms
SPECIFIC FUNCTIONS OF THE PML ISOFORMS
The implication of PML isoforms in various cellular processes is
due to their ability to interact with different partners either in the
nucleus or in the cytoplasm. Although the PML isoforms may have
related functions due to their common functional RBCC/TRIM
domain, increasing evidences suggest that each PML isoform
possesses distinct functions mediated by its specific C-terminal
sequence (Table 5). It has been reported that, in various cell lines,
the endogenous expression of the PMLIII, PMLIV, and PMLV
isoforms is quantitatively less as compared to PMLI and PMLII
(Condemine et al., 2006).
NUCLEAR PML ISOFORMS
Nuclear PML is considered to be the organizer protein of the PML
NBs. All six human nuclear PML isoforms are able to form NBs
when expressed in PML-negative cells (Brand et al., 2010). All
nuclear PML isoforms (PMLI to PMLVI), but not the cytoplasmic
one (PMLVIIb), function as a positive regulator of IFNγ signaling
Table 5 | Functions of specific PML isoforms.
PML isoforms and exons1 Specific isoform functions Reference
PMLI (882 AA)
1-2-3-4-5-6-7a-8a-9 Interacts with AML1 and stimulates myeloid cell
differentiation
Nguyen et al. (2005)
Interacts with and is degraded by ICP0 in a
SUMO-independent manner
Cuchet-Lourenco et al. (2012)
PMLII (829 AA)
1-2-3-4-5-6-7a-7b Implicated in Ad5 virus-induced PML NB disruption Leppard et al. (2009)
Interacts with Ad5 E1A-13S and enhances viral transcription Berscheminski et al. (2013)
PMLIII (641 AA)
1-2-3-4-5-6-7a-ri7ab*-7b*2,3 Controls centrosome duplication Xu et al. (2005)
PMLIV (633 AA)
1-2-3-4-5-6-7a-8a-8b Regulates apoptosis, senescence, and DNA damage Bischof et al. (2002); Guo et al. (2000);
Pearson et al. (2000)
Interacts with p53, PU.1, TERT, TRF1, and TIP60 Fogal et al. (2000); Oh et al. (2009); Yoshida
et al. (2007); Wu et al. (2009); Yu et al. (2010)
Destabilizes c-Myc Buschbeck et al. (2007)
Inhibits VZV, EMCV, and rabies virus Maroui et al. (2011); Reichelt et al. (2011);
Blondel et al. (2010)
PMLV (611 AA)
1-2-3-4-5-6-7a-ri7ab3 Acts as a potential scaffold of PML NBs Weidtkamp-Peters et al. (2008)
Forms NBs and recruits Daxx and Sp100 via aa 591–611 Geng et al. (2012)
PMLVI (560 AA)
1-2-3-4-5-6-riGTAGGGAG-7a*4 Resists to As2O3-induced degradation due to the lack of the
SIM in exon 7a
Maroui et al. (2012)
PMLVIIB (435 AA)
1-2-3-4-7b* Activates TGFβ signaling Lin et al. (2004)
Carracedo et al. (2011)
cPML∆5-6/PMLIb to VIb (423 aa)
1-2-3-4-7a*4,5 Sequesters ICP0 in the cytoplasm and confers resistance to
HSV-1
McNally et al. (2008)
1The exons encoding sequences that are specific to a single PML isoform are underlined.
2Due to a frameshift, the protein sequences encoded by exon 7b* in PMLIII (VHGAHGDRRATVLASPLLASPLLASPLLASPVSAESTRSLQPALWHIPPPSLASPPAR) and
7b* in PMLVIIb (LPPPAHALTGPAQSSTH) are shorter and different from the sequence encoded by exon 7b in PMLII (259 aa).
3The protein sequence encoded by the retained introns ri7ab* in PMLIII (VSSSPQSEVLYWK) is different from that of the ri7ab of PMLV (VSGPEVQARTPASPHFRSQ-
GAQPQQVTLRLALRLGNFPVRH).
4Due to a frameshift, the protein sequence encoded by the exon 7a* (RNALW) in PMLVI and the PMLIb to PMLVIb isoforms, which lack exons 5 and 6, is different
from that of the SIM-encoding exon 7a (EERVVVISSEDSDAENS) in PMLI to PMLV.
5cPML∆5-6 corresponds to the cytoplasmic PML isoform, which lacks exons 5 and 6. Note that alternative splicing of exons 5 and 6 in the PMLI to PMLVI mRNA
variants introduces a frameshift and generates proteins corresponding to PMLIb to PMLVIb, all of which have a STOP codon at the beginning of exon 7a, termed here
7a* and which code for the same cytoplasmic protein, cPML∆5-6, corresponding to PMLIb to PMLVIb in the Jensen nomenclature.
ri, retained intron.
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and this process requires PML SUMOylation (El Bougrini et al.,
2011). The functions of the nuclear PML isoforms have been stud-
ied mainly in the context of their localization within the NBs where
PML is concentrated. To date, their biological functions in the
nucleoplasm remains largely unexplored despites the fact that the
majority of PML expressed in the cell is dispersed diffusely in the
nucleoplasm.
PMLI interacts with acute myeloid leukemia 1 (AML1) to
induce differentiation of the hematopoietic cell lineage (Nguyen
et al., 2005). Also, PMLI interacts and colocalizes with HSV-1 ICP0
owing to its specific C-terminus sequence encoded by exon 9.
This leads to SUMO-independent degradation of PMLI by ICP0
(Boutell et al., 2011; Cuchet-Lourenco et al., 2012). To the con-
trary, the other nuclear PML isoforms are degraded by ICP0 using
a SUMO-dependent mechanism.
PMLII binds specifically to adenovirus type 5 (Ad5) E4 Orf3 via
its C-terminus. This interaction, which is conferred by 40 amino
acid residues encoded by PMLII exon 7b (amino acids 645–684),
mediates the virus-induced PML NB disruption (Leppard et al.,
2009). Recently, it has been reported that PMLII also physically
interacts with Ad5 E1A–13S to positively activate viral transcrip-
tion (Berscheminski et al., 2013). This suggests that, in contrast to
PML NB-associated antiviral defense, PMLII may assist Ad5 viral
transcription.
PMLIII was shown (using PML isoform-specific antibodies) to
play a direct role in the control of centrosome duplication through
suppression of Aurora A activation, which prevents centrosome
reduplication (Xu et al., 2005).
PMLIV is the most studied PML isoform. PMLIV specifically
interacts with many cellular proteins such as p53, PU.1, TERT
(telomerase reverse transcriptase), TRF1 (telomeric repeat bind-
ing factor 1), and the histone acetyl transferase TIP60 (Fogal et al.,
2000; Yoshida et al., 2007; Oh et al., 2009; Wu et al., 2009; Yu
et al., 2010). PMLIV recruits and activates p53 in PML NBs and
enhances apoptosis and senescence following various stimuli (Guo
et al., 2000; Pearson et al., 2000; Bischof et al., 2002; Bernardi
et al., 2004). Although several PML isoforms are able to interact
with c-Myc, the ability to destabilize c-Myc is specific to PMLIV
(Buschbeck et al., 2007). In addition, studies performed with all
PML isoforms demonstrate that only PMLIV protects cells from
infection with rabies virus, VZV, or EMCV (Blondel et al., 2010;
Maroui et al., 2011; Reichelt et al., 2011). This demonstrates the
importance of exons 8a and 8b in mediating protein interactions
and, thus, specific functions.
PMLV was identified as a potential scaffold for the PML NB
since comparative kinetic analyses with various GFP-tagged PML
isoforms reveal that PMLV exhibits the longest residence time
(Weidtkamp-Peters et al., 2008). This suggests that specific C-
terminus of PMLV, which harbors the translated intron 7ab, may
contribute to PML NB structural stability. Also, the 21-amino acid-
long region within PMLV (amino acids 591–611) is sufficient for
NB formation and the recruitment of PML NB partners includ-
ing Daxx and Sp100. This process occurs independently of the
N-terminal RBCC domain and endogenous PML (Geng et al.,
2012).
PMLVI is the shortest nuclear isoform encoded only by exons
1–6 due to a STOP codon located at the beginning of exon 7a.
Therefore it does not contain the SIM hydrophobic core and the
CK2-phosphorylation sites. As compared to all other nuclear iso-
forms, PMLVI was shown to be resistant to As2O3-induced PML
degradation due to the lack of the SIM hydrophobic core (Maroui
et al., 2012).
CYTOPLASMIC PML ISOFORMS
Although the majority of PML proteins are in the nucleus, nucleo-
cytoplasmic fractionation reveals that a fraction of PML is found
in the cytoplasm (Lin et al., 2004; Giorgi et al., 2010). Emerg-
ing data suggest the implication of cytoplasmic PML in cytokine
signaling (Lin et al., 2004), apoptosis (Giorgi et al., 2010), and
antiviral defense (McNally et al., 2008).
Alternative splicing can generate various cytoplasmic PML iso-
forms. PMLVIIb, which lacks exons 5 and 6, is cytoplasmic (Jensen
et al., 2001). Also, an identical cytoplasmic PML protein, cPML∆5-
6, can be generated from all PML mRNA variants that lack exons
5 and 6 (corresponding to PMLIb to PMLVIb as mentioned above
in Section Nomenclature of PML Isoforms).
Furthermore, different cytoplasmic PML proteins with their
preserved specific C-terminal sequences can be generated, poten-
tially, from PML mRNA variants missing exons 4, 5, and 6 (PMLIc
to PMLVIc). However, further investigations are needed to demon-
strate that all these cytoplasmic isoforms, indeed, are expressed
endogenously.
The first evidence, revealing a cytoplasmic function for PML,
was obtained for PMLVIIb or cPML, where cPML is “cPML3
3-7” missing exons 4-5-6 that corresponds to PMLIVc in the
Jensen nomenclature (Lin et al., 2004; Carracedo et al., 2011).
This study showed that cytoplasmic PML is essential for the activa-
tion of transforming growth factor beta (TGFβ) signaling through
its interaction with SMAD2/3 and Smad anchor for receptor
activation (SARA).
Another study showed that HSV-1 infection leads to an alter-
ation of PML pre-mRNA splicing which leads to the elimination of
exons 5 and 6 and the insertion of a STOP codon at the beginning
of exon 7a. The resulting translation product is cPML∆5-6. The
expression of cPML∆5-6 confers resistance to HSV-1 by seques-
tering the immediate early HSV-1 protein ICP0 in the cytoplasm
(McNally et al., 2008). The anti-HSV-1 effect of cPML∆5-6 is
higher in wild-type MEFs as compared to PML−/− MEFs which
suggests the participation of other PML isoforms (McNally et al.,
2008). These findings provide the first example of a protective
effect of cytoplasmic PML against viral infection.
CONCLUDING REMARKS
In this review, we have discussed the nomenclature and struc-
tural organization of PML isoforms in order to clarify the various
designations and classifications found in different databases. We
also have summarized the functions mediated by the specific
C-terminal end of the different PML isoforms. However, much
remains to be discovered about the role of the PML isoforms
in the different cellular compartments, i.e., the cytoplasm, the
nucleoplasm, and the nuclear matrix-associated NBs.
The different names given to identical PML isoforms in the
different classification systems often make PML nomenclature
confusing in publications. Therefore, it is important to include
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the accession numbers in future publications for the proper
identification of the specific PML isoform(s) being studied.
Additional studies performed with all the PML isoforms
undoubtedly will clarify further the relationships between spe-
cific functions and specific isoforms. Also, it will be of interest to
determine whether or to what extent a function attributed to one
isoform is maintained in the absence of the other isoforms. Con-
sequently, the analysis of specific PML isoforms may reveal novel
interacting partners and functions.
Recently, it has been reported that, contrary to PML NB-
associated antiviral defense, PMLII interacts with Ad5 E1A-13S to
positively activate viral transcription. Further studies will deter-
mine whether other viral proteins could take direct advantage of
PML to increase viral production.
In addition to its role in the nucleus, PML has been found to
accumulate in the cytoplasm and to play a critical role in cytokine
signaling, antiviral response, and apoptosis. This demonstrates
that PML also exerts specific functions in this compartment. Fur-
ther research is needed to confirm which of the cytoplasmic PML
isoforms expected from alternative splicing are, indeed endoge-
nously expressed and whether post-translational modifications
regulate their functions.
Diverse cellular stimuli induce proteasome-dependent PML
degradation through alternative or potentially complementary
pathways, some of which depend upon PML SUMOylation. Mul-
tiple cellular pathways for degradation of PML have emerged
at present. They use as key players CK2, USP7, Pin1, and
the three E3 ubiquitin ligases, E6AP, Arkadia, and RNF4. The
best understood pathway, at present, is the RNF4-dependent
pathway. Further investigations are required to unravel the
respective involvement of E6AP, RNF4, and Arkadia in PML
degradation in response to As2O3. Whereas RNF4 and Arka-
dia require PML SUMOylation, the Cullin3-KLHL20 ubiqui-
tin ligase, acting in the Pin1 pathway, and E6AP can ubiqui-
tinate unSUMOylated PML. The E3 ubiquitin ligases involved
in the CK2 and USP7 PML degradation pathways are still
unknown. Whether these different pathways cooperate under
certain physiological or pathological conditions remains to be
elucidated.
The implication of RNF4 in PML degradation in response
to As2O3 is well demonstrated. Interestingly, while this review
was under revision, it was shown that RNF4 ubiquitinates poly-
SUMOylated Nrf2, leading to degradation of the modified Nrf2
in PML NBs in a proteasome-dependent manner (Malloy et al.,
2013). Whether RNF4 can induce degradation of other SUMOy-
lated and NB-associated proteins is unknown. As the overexpres-
sion of RNF4 alone is sufficient to induce a proteasome-dependent
PML degradation (Percherancier et al., 2009), it will be interest-
ing to assess whether RNF4 expression is increased in cancer and
whether this can be correlated with a decrease of PML expression
and tumor aggressiveness.
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